Bicycle Therapeutics plc (BCYC)
| Previous close | 22.68 |
| Open | 22.80 |
| Bid | 22.64 x 200 |
| Ask | 22.77 x 200 |
| Day's range | 22.45 - 23.33 |
| 52-week range | 12.54 - 28.91 |
| Volume | |
| Avg. volume | 402,651 |
| Market cap | 860.719M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
CAMBRIDGE, England & BOSTON, April 24, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of two abstracts for poster presentation at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago.
- Business Wire
Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, England & BOSTON, April 02, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 9, 2024, at 11 a.m. ET.
- Business Wire
Bicycle Therapeutics to Present at the AACR Annual Meeting 2024
CAMBRIDGE, England & BOSTON, March 05, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of three abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego on April 5-10.
